LUSPATERCEPT RESPONSE IN NEW SUBPOPULATIONS OF PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): UPDATE OF THE PACE STUDY

被引：1

作者：

Platzbecker, U. ^{[1
]}

Germing, U. ^{[2
]}

Goetze, K. ^{[3
]}

Kiewe, P. ^{[4
]}

Wolff, T. ^{[5
]}

Mayer, K. ^{[6
]}

Chromik, J. ^{[7
]}

Radsak, M. ^{[8
]}

Wilson, D. ^{[9
]}

Zhang, X. ^{[9
]}

Laadem, A. ^{[10
]}

Sherman, M. ^{[9
]}

Attie, K. ^{[9
]}

Linde, P. ^{[9
]}

Giagounidis, A. ^{[11
]}

机构：

[1] Univ Klinikum Carl Gustav Carus, Dresden, Germany

[2] Univ Klinikum Dusseldorf, Dusseldorf, Germany

[3] Tech Univ Munich, Klinikum Rechts Isar, Dept Med Hematol & Med Oncol 3, Munich, Germany

[4] Oskar Helene Heim, Onkol Schwerpunkt, Berlin, Germany

[5] OncoRes Lerchenfeld UG, Hamburg, Germany

[6] Univ Hosp Bonn, Bonn, Germany

[7] Goethe Univ, Univ Klinikum Frankfurt, Frankfurt, Germany

[8] Johannes Gutenberg Univ Mainz, Mainz, Germany

[9] Acceleron Pharma, Cambridge, MA USA

[10] Celgene Corp, Summit, NJ USA

[11] Marien Hosp, Dusseldorf, Germany

来源：

LEUKEMIA RESEARCH | 2017年 / 55卷

关键词：

D O I：

10.1016/S0145-2126(17)30158-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S31 / S31

页数：1

共 50 条

[1] Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Fenaux, Pierre
Platzbecker, Uwe
Mufti, Ghulam J.
Garcia-Manero, Guillermo
Buckstein, Rena
Santini, Valeria
Diez-Campelo, Maria
Finelli, Carlo
Cazzola, Mario
Ilhan, Osman
Sekeres, Mikkael A.
Falantes, Jose F.
Arrizabalaga, Beatriz
Salvi, Flavia
Giai, Valentina
Vyas, Paresh
Bowen, David
Selleslag, Dominik
DeZern, Amy E.
Jurcic, Joseph G.
Germing, Ulrich
Goetze, Katharina S.
Quesnel, Bruno
Beyne-Rauzy, Odile
Cluzeau, Thomas
Voso, Maria-Teresa
Mazure, Dominiek
Vellenga, Edo
Greenberg, Peter L.
Hellstrom-Lindberg, Eva
Zeidan, Amer M.
Ades, Lionel
Verma, Amit
Savona, Michael R.
Laadem, Abderrahmane
Benzohra, Aziz
Zhang, Jennie
Rampersad, Anita
Dunshee, Diana R.
Linde, Peter G.
Sherman, Matthew L.
Komrokji, Rami S.
List, Alan F.
NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (02): : 140 - 151
[2] Mutational Profile and Analysis of Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Luspatercept: Phase 2 PACE-MDS Study
Platzbecker, Uwe
Kiewe, Philipp
Germing, Ulrich
Gotze, Katharina S.
Mayer, Karin
Radsak, Markus P.
Wolff, Thomas
Chromik, Joerg
Wilson, Dawn
Zhang, Xiaosha
Rovaldi, Chris
Laadem, Abderrahmane
Sherman, Matthew Leigh
Attie, Kenneth Morris
Reynolds, Joseph
Linde, Peter Guest
Giagounidis, Aristoteles
BLOOD, 2017, 130
[3] Long-Term Efficacy and Safety of Luspatercept in Lower-Risk Myelodysplastic Syndromes (MDS): Phase 2 PACE-MDS Study
Platzbecker, Uwe
Kiewe, Philipp
Germing, Ulrich
Goetze, Katharina
Mayer, Karin
Radsak, Markus
Wolff, Thomas
Chromik, Joerg
Reynolds, Joseph
Barron, Carolyn
Zhang, Xiaosha
Laadem, Abderrahmane
Attie, Kenneth
Giagounidis, Aristoteles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S319 - S320
[4] Luspatercept in the treatment of lower-risk myelodysplastic syndromes
Chan, Onyee
Komrokji, Rami S.
FUTURE ONCOLOGY, 2021, 17 (12) : 1473 - 1481
[5] Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study.
Platzbecker, Uwe
Giagounidis, Aristoteles
Kiewe, Philipp M.
Germing, Ulrich
Gotze, Katharina S.
Mayer, Karin
Radsak, Markus
Wolff, Thomas
Chromik, Joerg
Reynolds, Joseph
Barron, Carolyn
Rovaldi, Chris
Suragani, Rajasekhar N. V. S.
Zhang, Xiaosha
Laadem, Abderrahmane
Linde, Peter G.
Sherman, Matthew L.
Oelschlaegel, Uta
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
Platzbecker, Uwe
Goetze, Katharina S.
Kiewe, Philipp
Germing, Ulrich
Mayer, Karin
Radsak, Markus
Wolff, Thomas
Chromik, Joerg
Sockel, Katja
Oelschlaegel, Uta
Haase, Detlef
Illmer, Thomas
Al-Ali, Haifa Kathrin
Silling, Gerda
Reynolds, Joseph G.
Zhang, Xiaosha
Attie, Kenneth M.
Shetty, Jeevan K.
Giagounidis, Aristoteles
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (33) : 3800 - +
[7] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
Giagounidis, A.
Germing, U.
Goetze, K.
Kiewe, P.
Wolff, T.
Mayer, K.
Chromik, J.
Radsak, M.
Wilson, D.
Zhang, X.
Laadem, A.
Sherman, M. L.
Attie, K. M.
Linde, P. G.
Platzbecker, U.
HAEMATOLOGICA, 2017, 102 : 264 - 264
[8] Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial
Platzbecker, Uwe
Zhu, Yiming
Ha, Xianwei
Risueno, Alberto
Chan, Esther
Zhang, George
Dunshee, Diana R.
Acar, Melih
Shetty, Jeevan K.
Ito, Rodrigo
MacBeth, Kyle
Santini, Valeria
Garbowski, Maciej W.
Fenaux, Pierre
Schwickart, Martin
BLOOD, 2020, 136
[9] The Effect Of Luspatercept On Erythropoiesis Biomarkers In MEDALIST Trial Patients With Lower-Risk Myelodysplastic Syndromes
Platzbecker, Uwe
Zhu, Yiming
Ha, Xianwei
Risueno, Alberto
Chan, Esther
Zhang, George
Dunshee, Diana R.
Acar, Melih
Shetty, Jeevan K.
Ito, Rodrigo
MacBeth, Kyle
Santini, Valeria
Garbowski, Maciej W.
Fenaux, Pierre
Schwickart, Martin
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 188 - 189
[10] Real world efficacy of luspatercept in patients with lower-risk myelodysplastic syndromes/neoplasms (MDS); a single center study in a heavily pretreated cohort
Kometas, Marisa L.
Hoff, Fieke W.
Hyak, Jonathan
Irizarry-Gatell, Vivian
Velarde, Alejandro Marinos
Jackson, Clayton
Anderson, Julia
Kalkan, Fatma Neslihan
Geethakumari, Praveen Ramakrishnan
Thiebaud, Julio Alvarenga
Chen, Weina
Weinberg, Olga K.
Cantu, Miguel D.
Collins, Robert H.
Chung, Stephen S.
Madanat, Yazan F.
LEUKEMIA & LYMPHOMA, 2025,

← 1 2 3 4 5 →